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Abstract
Background: p27(Kip1) is a cyclin-dependent kinase inhibitor that inhibits G1-to-S phase transition of the cell cycle.
It is known that a relatively large number of nutritional and chemopreventive anti-cancer agents specifically up-
regulate expression of p27 without directly affecting the expression of other G1-to-S phase cell cycle regulatory
proteins including p21(Cip1Waf1). However, the upstream molecular signaling pathways of how these agents up-
regulate the expression of p27 have not been well characterized. The objective of this study was to identify such
pathways in human breast cancer cells in vitro using 4-hydroxytamoxifen, dexamethasone, and various retinoic
acids as examples of such anti-cancer agents.
Results: Experimental evidence presented in the first half of this report was obtained by transfecting human breast
cancer cells in vitro with proximal upstream region of p27 gene-luciferase reporter plasmids. 1) The evidence
indicated that 4-hydroxytamoxifen, dexamethasone, and various retinoic acids up-regulated expression of p27 in
both estrogen receptor-positive and negative human breast cancer cells in vitro. 2) The degree of up-regulation of
p27 expression by these anti-cancer agents in human breast cancer cells in vitro linearly correlated with the degree
of inhibition of methylnitrosourea (MNU)-induced rat mammary adenocarcinoma in vivo. 3) Lastly, up-regulation of
the expression of p27 was likely due to the activation of translation initiation rather than transcription of p27 gene.
The experimental evidence presented in the second half of this report was obtained by a combination of Western
immunoblot analysis and transfection analysis. It indicated that 4-hydroxytamoxifen and dexamethasone up-
regulated expression of p27 by down-regulating phosphorylation of eukaryotic translation initiation factor 4E
(eIF4E)-binding protein 1 (4E-BP1) at Ser65 and this phosphorylation was likely to be mediated by upstream
receptor tyrosine kinases/phosphoinositide-3-kinase/Akt/5’-AMP-activated protein kinase/mammalian target of
rapamycin (RTKs/PI3K/Akt/AMPK/mTOR) protein kinase signaling pathways. Retinoic acids up-regulated expression
of p27 without using either 4E-BP1 or RTKs/PI3K/Akt/AMPK/mTOR protein kinase signaling pathways.
Conclusions: 4-Hydroxytamoxifen and dexamethasone up-regulated translation initiation of p27 by down-
regulating 4E-BP1 phosphorylated at Ser65 and this down-regulation seemed to be mediated by upstream RTKs/
PI3K/Akt/AMPK/mTOR protein kinase signaling pathways. Retinoic acids also up-regulated translation initiation of
p27, but without using any of these pathways.
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Cyclin-dependent kinases (CDKs), together with cyclins,
their regulatory subunits, govern cell cycle progression
in eukaryotic cells. p27(Kip1) is a member of a family of
C D Ki n h i b i t o r s( C D I s )t h a tb i n dt oc y c l i n / C D Kc o m -
plexes and arrest cell cycle progression from G1 to S
phase.
In early G1 phase, mitogens increase D-type cyclins,
which bind and activate CDK4 and CDK6 [see reference
[1] for an excellent review]. Subsequent activation of
cyclin E and cyclin A/CDK2 complexes regulate S phase
entry and progression. Two families of CDIs regulate
the cyclin/CDK complexes [1-6], namely (a) the inhibi-
t o ro fC D K 4( I N K 4 )f a m i l ym e m b e r sa n d( b )m e m b e r s
of kinase inhibitor protein family, p27(Kip1), p57(Kip2)
and p21(Cip1Waf1), which bind and inhibit cyclin E and
cyclin A-bound CDK2. Although p27 and p21 are major
inhibitors of CDK2, they also promote G1 progression
by facilitating the assembly of cyclin D/CDK4 and cyclin
D/CDK6 complexes [7,8].
It is known that a relatively large number of nutri-
tional and chemopreventive anti-cancer agents specifi-
cally up-regulate expression of p27 in eukaryotic cells
without directly affecting other G1-to-S phase cell cycle
regulatory proteins including INK4s, p57(Kip2), p21
(Cip1Waf1), D-type cyclins, cyclin E, cyclin A, CDK2,
CDK4 and CDK6 [9,10]. For example, retinoic acids
(e.g., all-trans,9 - cis, and 13-cis) and dexamethasone spe-
cifically up-regulated expression of p27 in promotion-
sensitive (P+) JB6 mouse epidermal cells in vitro without
affecting cyclin D1, cyclin A and p21 [10]. Also, 4-
hydroxytamoxifen (but not tamoxifen), genistein and
daidzein (but not genistin), curcumin, taxifolin, retinoic
acids (e.g., all-trans and 9-cis) and dexamethasone up-
regulated expression of p27 in estrogen receptor-positive
human MCF7 breast cancer cells in vitro [10]. Similarly,
4-hydroxytamoxifen (but not tamoxifen), genistein and
daidzein (but not genistin), resveratrol, retinoic acids (e.
g., all-trans,9 - cis, and 13-cis) and dexamethasone up-
regulated expression of p27 in estrogen receptor-nega-
tive MDA-MB-231 human breast cancer cells in vitro
[10]. Additionally, numerous other nutritional and che-
mopreventive anti-cancer agents up-regulated expression
of p27 in MDA-MB-231 cells [10].
Despite all this information, however, very little is
known about the upstream molecular signaling pathways
of how these anti-cancer agents up-regulate the expres-
sion of p27. According to Slingerland, Hengst and other
investigators [1,11,12], p27 expression is believed to be
regulated at different levels including transcriptional
[13-16], translational [11,17-19], and post-translational
mechanisms including ubiquitin-proteasome-induced
degradation [20-23], complex association [24],
subcellular localization [25-30], and protein phosphory-
lation [12,30,31].
Previously, we identified four different upstream mole-
cular signaling pathways of p27 expression using
p27-luciferase reporter plasmids and numerous specific
inhibitors and stimulators of p27 expression [10]. (We
will call these four pathways as pathway #1, #2, #3 and
#4.). This approach was very efficient and sensitive in
identifying upstream molecular signaling pathways of
p27 expression, but it had a major drawback; namely, it
could not tell which specific anti-cancer agent uses
which specific pathway to up-regulate p27 expression.
To address this question, Western immunoblot analysis,
although cumbersome and not as sensitive as p27-luci-
ferase reporter assays, must have been performed. The
objective of the present study, therefore, was to perform
Western immunoblot analysis using 4-hydroxytamoxi-
fen, dexamethasone, and retinoic acids as examples of
anti-cancer agents to identify which specific upstream
molecular signaling pathway each one of these anti-can-
c e ra g e n t su s e st ou p - r e g u l a te the expression of p27 in
human breast cancer cells in vitro.
The results indicated that 4-hydroxytamoxifen and
dexamethasone up-regulated translation initiation of p27
by down-regulating the phosphorylation of eukaryotic
translation initiation factor 4E (eIF4E)-binding protein 1
(4E-BP1). The phosphorylation of 4E-BP1 seemed to be
down-regulated by upstream mTOR protein kinase
pathways including (a) receptor tyrosine kinases (RTKs)/
phosphoinositide-3-kinase (PI3K)/Akt and (b) 5’-AMP-
activated protein kinase (AMPK) and then tuberous
sclerosis complex (TSC)/mammalian target of rapamycin
(mTOR). Retinoic acids also up-regulated translation
initiation of p27, but they did so without using any of
these pathways including 4E-BP1.
Results
4-Hydroxytamoxifen, dexamethasone, all-trans-retinoic
acid and 9-cis-retinoic acid up-regulated expression of
p27 in both estrogen receptor-positive and -negative
human breast cancer cells in vitro
The diagram in Figure 1a shows the outline of how var-
ious anti-cancer agents specifically up-regulate expres-
sion of p27 and arrest cell cycle progression from G1 to
S phase. The upstream molecular signaling pathways of
how these anti-cancer agents up-regulate the expression
of p27 was investigated using a p27-luciferase reporter
plasmid containing proximal upstream region (-1797) of
p27 gene (p27-Kpn I) (Figure 1b) [32]. This plasmid was
transfected into the estrogen receptor (ER) - positive as
well as negative human breast cancer cells in vitro and
then the transfected cells were exposed to 1 μMe a c ho f
the following five different anti-cancer agents, namely
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Page 2 of 19Figure 1 4-Hydroxytamoxifen, dexamethasone, all-trans-retinoic acid and 9-cis-retinoic acid up-regulate expression of p27 in both
estrogen receptor-positive and -negative human breast cancer cells in vitro. (a) Outline of how various anti-cancer agents specifically up-
regulate expression of p27 and arrest the progression of cell cycle from G1 to S phase. (b) Schematic drawing of the luciferase reporter plasmid
containing proximal 5’-upstream region (-1797) of the p27 gene (-1797 p27 (p27-Kpn I)). 4-Hydroxytamoxifen (but not tamoxifen),
dexamethasone, all-trans-retinoic acid and 9-cis-retinoic acid up-regulated relative luciferase activity of p27 in (c) estrogen receptor (ER)-positive
MCF7 and (d) estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells in vitro. (e) Western immunoblot analysis of the
expression of p27 protein in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells in vitro. In all experiments, the cells were
exposed to 1 μM each of tamoxifen, 4-hydroxytamoxifen, dexamethasone, all-trans-retinoic acid or 9-cis-retinoic acid for 24 hours. All assays were
performed in triplicates and repeated three times.
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trans -retinoic acid (atRA), and 9-cis-retinoic acid
(9cRA) for 24 hours. The results (Figure 1c and 1d)
indicated first that tamoxifen did not up-regulate the
expression of p27 in both MDA-MB-231 and MCF7
cells, but other four anti-cancer agents up-regulated the
expression of p27 in both ER-positive (also LKB1-posi-
tive) and ER-negative (also LKB1-negative) human
breast cancer cells in vitro. Next, expression of p27 pro-
tein in ER-negative MDA-MB-231 cells was examined
by Western immunoblot analysis. The results (Figure
1e) indicated that tamoxifen and all-trans-retinoic acid
(atRA) did not up-regulate the expression of p27 pro-
tein, but 4-hydroxitamoxifen, dexamethasone and 9-cis-
r e t i n o i ca c i d( 9 c R A )d i d .I ts h o u l db en o t e dt h a t ,
although all-trans-retinoic acid (atRA) did not up-regu-
late the expression of p27 protein in a statistically signif-
icant manner, average expression of p27 protein tended
to be higher in the presence of all-trans-retinoic acid
(atRA) than in the absence of all-trans-retinoic acid
(atRA).
In summary, these results suggested that 4-hydroxyta-
moxifen (but not tamoxifen), dexamethasone, 9-cis-reti-
noic acid (9cRA) and probably all-trans-retinoic acid
(atRA) up-regulated the expression of p27 in both ER-
positive and negative human breast cancer cells in vitro
(Figures 1c, 1d and 1e).
The degree of up-regulation of p27 in human breast
cancer cells in vitro linearly correlates with the degree of
inhibition of methylnitrosourea (MNU)-induced rat
mammary adenocarcinoma in vivo
In the next experiment, we used various chemically
synthesized retinoic acids to investigate whether the
degree of up-regulation of the -1797 p27-luciferase
reporter activity (p27-Kpn I) in human breast cancer
cells in vitro correlates with the degree of inhibition of
methylnitrourea (MNU)-induced rat mammary adeno-
carcinoma in vivo. The results presented in the Figures
2a and 2b indicated that the up-regulation of the in vitro
p27-luciferase reporter activity by various retinoic acids
indeed correlated with the in vivo activity of the inhibi-
tion of MNU-induced rat mammary cancer by the same
retinoic acids [33]. The Figure 2c graphically represents
the results in Figure 2a; it shows that the in vitro and
in vivo parameters of the inhibition of breast cancer lin-
early correlated with each other and the correlation is
statistically significant. One note of caution about this
linear correlation: if a particular anti-cancer agent (e.g.,
tamoxifen) needs to be metabolized into an ultimately
active anti-cancer agent (e.g., 4-hydroxytamoxifen) in
vivo,t h e nt h ein vitro and in vivo activities of this parti-
cular anti-cancer agent (e.g., tamoxifen) do not follow
this linear correlation.
Deletion analysis suggested that 4-hydroxytamoxifen,
dexamethasone, all-trans-retinoic acid and 9-cis-retinoic
acid activated the proximal 5’-upstream region (-1797)
of p27 gene through its 5’-untranslated region
(5’-UTR) (-575)
To determine the core activation elements in the proxi-
mal 5’-upstream region (-1797) of p27 gene, ER-negative
MDA-MB-231 human breast cancer cells were trans-
fected with the following deletion mutants of -1797 p27
(Figure 3a): namely -1797 p27 (p27-Kpn I) [32], -774 p27
(p27-Apa I) [32] and -575 p27 (p27-5’-UTR) [11,34]. The
transfected cells were then treated with tamoxifen (Figure
3b), 4-hydroxytamoxifen (Figure 3c), dexamethasone
(Figure 3d), all-trans-retinoic acid (atRA) (Figure 3e) and
9-cis-retinoic acid (9cRA) (Figure 3f).
The results suggested that 4-hydroxytamoxifen (but
not tamoxifen), dexamethasone, all-trans-retinoic acid
(atRA), and 9-cis-retinoic acid (9cRA) activated proximal
5’-upstream region (-1797) of the p27 gene through -575
p27 (5’-untranslated region (5’-UTR) of p27 gene).
When the regions shorter than -575 p27 (p27-5’UTR) -
namely -435 p27 (p27-MB) [32] and -417 p27 (p27-
IRES) [11,34] - were tested, the activities tended to be
either reduced or stay more or less constant (data not
shown).
The -575 p27 (5’-untranslated region (5’-UTR) of p27
gene) was unlikely to contain any cryptic transcription
factor binding sites
To investigate whether -575 p27 (p27-5’-UTR) con-
tained any cryptic transcription factor binding sites, the
luciferase activity of the 5’-untranslated region (5’-UTR)
(-575) of p27 gene (p27-5’-UTR) was stimulated by
tamoxifen, 4-hydroxytamoxifen, all-trans-retinoic acid
(atRA), 9-cis-retinoic acid (9cRA), UAB30 [33], 4-
methyl-UAB30 (4meUAB30) [33], or dexamethasone in
the presence and absence of the antibiotic actinomycin
D, an inhibitor of transcription. The diagram in Figure
4a shows the schematic drawing of the pGL3-control
luciferase reporter plasmid without insert and with p27-
5’-UTR insert used for this study. This plasmid - pGL3
control - contained SV40 promoter in its backbone. The
preliminary study using pGL3 control without p27-5’-
UTR insert had demonstrated that none of the agents
or vehicle (DMSO) did not exert any spurious effects on
the SV40 promoter when human breast cancer cell lines
were used.
The results shown in the left half of the Figure 4b
indicated that, in the absence of actinomycin D, only 4-
hydroxytamoxifen up-regulated the p27-luciferase activ-
ity of -575 p27 (p27-5’-UTR) significantly above that of
vehicle (DMSO) in MDA-MB-231 cells; as expected,
tamoxifen failed to up-regulated it. The results shown in
the right half of the Figure 4b indicated that the
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Page 4 of 19Figure 2 The degree of up-regulation of p27 expression in human breast cancer cells in vitro linearly correlates with the degree of
inhibition of methylnitrosourea (MNU) -induced rat mammary adenocarcinoma in vivo. (a) Various chemically synthesized retinoic acids
were used to investigate whether the degree of up-regulation of -1797 p27 gene-luciferase reporter (p27-Kpn I) activity in estrogen receptor
(ER)-negative MDA-MB-231 human breast cancer cells in vitro correlates with the degree of inhibition of methylnitrourea (MNU) -induced rat
mammary adenocarcinoma in vivo [33]. The cells were exposed to 1 μM each of the retinoic acids for 24 hours. In vitro transfection assays were
performed in triplicates and repeated three times. (b) Chemical structure of the retinoic acids used in this experiment [33]. (c) Graphical
representation of the results in Figure 2a above.
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Page 5 of 19Figure 3 Deletion analysis indicates that 4-hydroxytamoxifen, dexamethasone, all-trans-retinoic acid (atRA) and 9-cis-retinoic acid
(9cRA) activate the proximal 5’-upstream region (-1797) of p27 gene through its 5’-untranslated region (5’-UTR) (-575). (a) The 5’-
deletion mutants of -1797 p27 (p27-Kip I) used in this experiment were -774 p27 (p27-Apa I) and -575 p27 (p27-5’UTR). Two additional deletion
mutants, -435 p27 (p27-MB) and -417 p27 (p27-IRES), were also used in this experiments, but the data are not shown. The estrogen receptor (ER)-
negative MDA-MB-231 human breast cancer cells were transfected with these deletion mutants and then exposed to 1 μM each of (b)
tamoxifen, (c) 4-hydroxytamoxifen (4-OH-tamoxifen), (d) dexamethasone, (e) all-trans-retinoic acid (atRA) and (f) 9-cis-retinoic acid (9cRA) for 24
hours. All assays were performed in triplicates and the transfection experiments were repeated three times.
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Page 6 of 19Figure 4 The 5’-untranslated region (5’-UTR) (-575) of p27 gene is unlikely to contain cryptic transcription factor binding sites.( a )
Schematic drawing (adapted from the references [11,34]) of the pGL3-control-p27-5’-UTR-luciferase reporter plasmid. (b) The ER-negative MDA-
MB 231 cells were transfected with -575 p27 (p27-5’-UTR) -luciferase reporter plasmid and then treated with either vehicle or actinomycin D(0.5
μg/ml) [55]. One hour after the addition of either vehicle or actinomycin D, the cells were exposed to vehicle, tamoxifen (1 μM) or 4-
hydroxytamoxifen (1 μM) for another 24 hours. (c) Same as in Figure 4b above, except that the cells were exposed to vehicle, all-trans-retinoic
acid (atRA) (1 μM) or 9-cis-retinoic acid (9cRA) (1 μM) for 24 hours. (d) Same as in Figure 4b above, except that the cells were exposed to
vehicle, 4-methyl-UAB30 (4meUAB30) (1 μM) or UAB30 (1 μM) for 24 hours. (e) Same as in Figure 4b, except that the cells were exposed to
vehicle or dexamethasone (1 μM). All assays were performed in triplicates and the transfection experiments were repeated three times.
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(DMSO) alone decreased the baseline p27-luciferase
activity of -575 p27 (p27-5’-UTR) by about 50% com-
pared to the baseline luciferase activity observed in the
absence of actinomycin D. Despite this decrease in the
baseline p27-luciferase activity in the presence of actino-
mycin D, 4-hydroxytamoxifen significantly up-regulated
the p27-luciferase activity of -575 p27 (p27-5’-UTR)
above that of the vehicle (DMSO) in the presence of
actinomycin D. These results suggested that the tran-
scriptional mechanisms were not involved in a signifi-
cant manner in the up-regulation of the luciferase
activity of -575 p27 (p27-5’-UTR) by 4-hydroxytamoxi-
fen, precluding the involvement of any cryptic transcrip-
tion factor binding sites in this region. What was more
surprising was the finding that tamoxifen, which had
previously been inactive in the absence of actinomycin
D, now significantly up-regulated the p27-luciferase
activity of -575 p27 (p27-5’-UTR) in the presence of
actinomycin D, suggesting that the overall rate of global
transcription might somehow exerted effects on the
p27-luciferase activity of -575 p27 (p27-5’-UTR) in
MDA-MB-231 cells.
Similar results were obtained with all-trans-retinoic
acid (atRA) and 9-cis-retinoic acid (9cRA) (Figure 4c),
4-methyl-UAB30 (4meUAB30) [33] and UAB30 [33]
(Figure 4d) and dexamethasone (Figure 4e). These
results suggested that -575 p27 (5’-untranslated region
(5’-UTR) of p27 gene) was unlikely to have contained
any cryptic transcription factor binding sites.
In summary, these results suggested that 4-hydroxyta-
moxifen, dexamethasone and various retinoic acids up-
regulated the expression of p27 by activating translation,
rather than transcription, of p27 gene via its 5’-untrans-
lated region (5’-UTR) (-575).
4-Hydroxytamoxifen and dexamethasone up-regulated
the expression of p27 by down-regulating 4E-BP1
phosphorylated at Ser65 and this down-regulation was
likely to be mediated by upstream RTKs/Akt/AMPK/mTOR
protein kinase signaling pathways. Retinoic acids also up-
regulated the expression of p27 but they did so without
using any of these pathways
Previous study identified four potential upstream mole-
cular signaling pathways that might be involved in the
up-regulation of the expression of p27 by these anti-
cancer agents in the ER-negative MDA-MB-231 human
breast cancer cells in vitro [10]. These four potential
upstream molecular signaling pathways of p27 were
pathway #1 (Figures 5a and 5b), pathway #2 (Figures 5a
and 5b), pathway #3 (Figure 5b) and pathway #4 (Figure
5b). To investigate which one of these upstream mole-
cular signaling pathways was used by 4-hydroxitamoxi-
fen, dexamethasone, all-trans-retinoic acid (atRA) and
9-cis-retinoic acid (9cRA) to up-regulate the expression
of p27, Western immunoblot analysis was performed
using the ER-negative MDA-MB-231 human breast can-
cer cells in vitro (Figures 5 and 6). We investigated only
the pathways #1, #2 and #3 in this Western immunoblot
study; the pathway #4 was not investigated.
Most notable result of this Western immunoblot study
was the expression of eukaryotic translation initiation
repressor protein 4E-BP1 (eukaryotic translation initia-
tion factor 4E-binding protein 1) phosphorylated at
Ser65. As the results in Figure 5c indicate, expression of
total 4E-BP1 was neither up nor down-regulated by any
of the anti-cancer agents tested (Figure 5c). However,
the 4E-BP1 phosphorylated at Ser65 was significantly
down-regulated by two of the anti-cancer agents tested,
namely 4-hydroxytamoxifen and dexamethasone (Figure
5d). The 4E-BP1 phosphorylated at Ser65 was neither
up nor down-regulated by tamoxifen, all-trans-retinoic
acid (atRA) or 9-cis-retinoic acid (9cRA) (Figure 5d).
These results suggested that 4-hydroxytamoxifen (but
not tamoxifen) and dexamethasone used either the
upstream molecular signaling pathway #1 or #2 or both
to up-regulate the expression of p27. They also sug-
gested that the two retinoic acids tested did not use
pathways#1 and #2 to up-regulate the expression of p27.
The second most notable result of this study was the
expression of the following two proteins which were sig-
nificantly up or down-regulated by one or more of these
anti-cancer agents tested: (a) one was AMPKa (5’-AMP-
activated protein kinase a)p h o s p h o r y l a t e da tT h r 1 7 2
(Figure 5f) and (b) another was Akt/PKB phosphorylated
at Thr308 (Figure 6b).
(a) In the case of AMPKa, expression of total AMPKa
was neither up nor down-regulated by any of the anti-
cancer agents tested (Figure 5e), but the expression of
AMPKa phsophorylated at Thr172 was up-regulated by
dexamethasone (Figure 5f). Therefore, it is reasonable to
assume that dexamethasone up-regulated the expression
of p27 by using upstream molecular signaling pathway
#2 (Figures 5a, 5b and 7).
(b) In the case of Akt/PKB, expression of total Akt/
PKB was neither up nor down-regulated by any of the
anti-cancer agents tested (Figure 6a), but the expression
of Akt/PKB phosphorylated at Thr308 was down-regu-
lated by 4-hydroxytamoxifen and dexamethasone (Figure
6b). Since 4-hydroxytamoxifen did not up-regulate the
expression of AMPKa phosphorylated at Thr172 (Figure
5 f ) ,i ti sl i k e l yt h a t4 - h y d roxytamoxifen used the
upstream molecular signaling pathway #1 exclusively to
up-regulate the expression of p27 (Figures 5a, 5b and 7).
As for dexamethasone, expression of p27 could have
been up-regulated by dexamethasone using either one
or both of the following two pathways: namely either (a)
dexamethasone used both pathways #1 and #2, or (b)
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Page 8 of 19Figure 5 4-Hydroxytamoxifen and dexamethasone up-regulate the expression of p27 by down-regulating phosphorylation of 4E-BP1
and this down-regulation is likely to be mediated by upstream Akt/AMPK/mTOR protein kinase signaling pathways. Retinoic acids
also up-regulate the expression of p27 but they do so without using any of these pathways. (a) and (b): Schematic drawings of the four
upstream molecular signaling pathways of p27 expression identified in our previous study [10]. These pathways are: pathway #1 (Figures 5a and
5b), pathway #2 (Figures 5a and 5b), pathway #3 (Figure 5b) and pathway #4 (Figure 5b). The specific inhibitors and activators used previously to
identify these four pathways are indicated next to each of the four pathways. From (c) to (f): Estrogen receptor (ER) -negative MDA-MB-231
human breast cancer cells in vitro were exposed to vehicle, tamoxifen (1 μM), 4-hydroxytamoxifen (1 μM), dexamethasone (1 μM), all-trans-
retinoic acid (atRA) (1 μM) or 9-cis-retinoic acid (9cRA) (1 μM) for 24 hours. Western immunoblot assays of the cells exposed to these anti-cancer
agents were performed using antibodies against (c) total 4E-BP1, (d) 4E-BP1 phosphorylated at Ser65, (e) total AMPK, and (f) AMPK
phosphorylated at Thr172. All assays were performed in triplicates and repeated three times. Abbreviations: RTK, receptor tyrosine kinase; PI3K,
phosphoinositide 3-kinase; PKB, protein kinase B; AMPK, 5’-AMP-activated protein kinase; TSC, tuberous sclerosis complex; mTOR, mammalian
target of rapamycin; eIF4E, eukaryotic translation initiation factor 4E; 4E-BP1, eIF4E-binding protein 1; MAPK, mitogen-activated protein kinase; Raf,
MAP kinase kinase kinase; MEK, MAP kinase kinase; MKK, MAP kinase kinase; MNK, MAP kinase-interacting kinase; eIF2a, eukaryotic translation
initiation factor 2a.
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Page 9 of 19Figure 6 Further results (continuation of Figure 5) of the Western immunoblot analysis.S a m ea si nF i g u r e5 ,e x c e p tt h a tW e s t e r n
immunoblot assays of the cells were performed using antibodies against (a) total Akt/PKB, (b) Akt/PKB phosphorylated at Thr308, (c) total IRS-1
(insulin receptor substrate 1), IRS-1 phosphorylated at Ser636/639, total PTEN (phosphatase and tensin homolog), PTEN phosphorylated at Ser380,
total eIF4E (eukaryotic translation initiation factor 4E), eIF4E phosphorylated at Ser209, total eIF2a (eukaryotic translation initiation factor 2a), and
eIF2a phosphorylated at Ser52, (d) PDGFRb (platelet-derived growth factor receptor b) phosphorylated at Tyr751, and (e) p44/42 MAPK or ERK1/2
phosphorylated at Thr202Tyr204. All assays were performed in triplicates and repeated three times.
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Page 10 of 19Figure 7 Schematic drawing of the four upstream molecular signaling pathways of p27 expression that could lead to activation of the
unusually long 5’-untranslated region (5’-UTR) (-575) of p27 mRNA by 4-hydroxytamoxifen, dexamethasone and retinoic acids. (a) The
two upstream molecular signaling pathways of p27 shown in Figure 5a are pathways #1 and #2. The pathway #1 consisted of receptor tyrosine
kinases/phosphoinositide 3-kinase/Akt/tuberous sclerosis complex/mammalian target of rapamycin/eukaryotic translation initiation factor 4E
(eIF4E) -binding protein 1 (RTKs/PI3K/Akt/TSC/mTOR/4E-BP1). The pathway #2 consisted of 5’-AMP-activated protein kinase (metabolic energy
sensor or cellular fuel gauge)/tuberous sclerosis complex/mammalian target of rapamycin/eIF4E-binding protein 1 (AMPK/TSC/mTOR/4E-BP1). (b)
In addition to these two pathways, two more upstream molecular signaling pathways of p27 expression were previously identified. They were
pathways #3 and #4. The pathway #3 consisted of receptor tyrosine kinases/MAPKs/eIF4E (RTKs/MAPKs/eIF4E). The pathway #4 consisted of
global hypomethylation of the 5’-7-methylguanosine (m
7G) cap of mRNAs. The specific inhibitors and activators used previously to identify these
four pathways are indicated next to each of the four pathways. The results of this study suggested that 4-hydroxytamoxifen used pathway #1
and dexamethasone primarily used pathway #2 to up-regulate the expression of p27. Dexamethasone could also use a portion of pathway #1
secondarily. We also believe, but could not conclude, that 4-hydroxytamoxifen up-regulated the expression of p27 using MAP kinase pathways
(Pathway #3 in Figures 5b and 7b). Retinoic acids up-regulated p27 expression without using pathways #1, #2 and #3. We propose a hypothesis
that retinoic acids are likely to have used pathway #4 to up-regulate the expression of p27. Abbreviations: see the legend of Figure 5.
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phorylated at Thr172 (pathway #2 in Figures 5a, 5b and
7), the up-regulation of which could have in turn secon-
darily down-regulated the Akt/PKB phosphorylated at
Thr308 (pathway #1 in Figures 5a, 5b and 7).
The third notable result was that all-trans-retinoic
acid (atRA) and 9-cis-retinoic acid (9cRA) neither up
nor down-regulated AMPKa phosphorylated at Thr172
(Figure 5f) and also neither up nor down-regulated Akt/
PKB phosphorylated at Thr308 (Figure 6b).
Expression of all other proteins examined by Western
immuno blot analysis was neither up nor down-regu-
lated by any of the anti-cancer agents tested. The pro-
teins examined in this study included (a) those in the
upstream molecular signaling pathway #1 of p27 expres-
sion (i.e., total IRS-1 (insulin receptor substrate 1) (Fig-
ure 6c), IRS-1 phosphorylated at Ser636/639 (Figure 6c),
PDGFRb (platelet-derived growth factor receptor b)
phosphorylated at Tyr751 (Figure 6d), total PTEN
(phosphatase and tensin homolog) (Figure 6c), PTEN
phosphorylated at Ser380 (Figure 6c)), (b) those in the
pathway #3 of p27 expression (p44/42 MAPK or ERK1/
2 phosphorylated at Thr202Tyr204 (Figure 6e), total
eIF4E (eukaryotic translation initiation factor 4E) (Figure
6c), eIF4E phosphorylated at Ser209 (Figure 6c)) and (c)
those involved in the endoplasmic reticulum stress (total
eIF2a (eukaryotic translation initiation factor 2a)) (Fig-
ure 6c) and eIF2a phosphorylated at Ser52 (Figure 6c)).
Discussion
The cell cycle repressor protein p27 exhibits a set of
unique characteristics that are not seen in other G1-to-S
phase cell cycle regulatory proteins including p21 [10].
First, a relatively large number of nutritional and che-
mopreventive anti-cancer agents specifically up-regulate
the expression of p27 without directly affecting expres-
sion of other G1-to-S phase cell cycle regulatory pro-
teins. Secondly, the degree of up-regulation of the
expression of p27 by these anti-cancer agents in human
breast cancer cell lines in vitro linearly and positively
correlates with the degree of inhibition of methylnitro-
sourea (MNU)-induced rat mammary adenocarcinoma
by the same anti-cancer agents. If a particular anti-can-
cer agent must be converted to an active metabolite in
vivo to up-regulate the expression of p27, the degree of
up-regulation of p27 in vitro and the degree of inhibi-
tion of MNU-induced rat mammary adenocarcinoma in
vivo by the same anti-cancer agent do not follow this
linear relationship. An example of such anti-cancer
agent is tamoxifen which must be converted to 4-hydro-
xytamoxifen in vivo to up-regulate the expression of
p27. Lastly, unlike other G1-to-S phase cell cycle regula-
tory proteins, expression of p27 is regulated primarily at
the level of translation, not at the level of transcription.
In the 1980s and 1990s, it was observed that, during the
progression of cell cycle, the level of p27 protein expres-
sion oscillated cyclically, but the level of p27 mRNA
remained constant. This observation led investigators to
suggest that, during the cell cycle, expression of p27 is
regulated primarily at the level of translation, not at the
level of transcription [11,17-19]. The expression of p27
during the cell cycle could also be regulated by various
post-translational mechanisms including ubiquitin-pro-
teasome-induced degradation [20-23], complex forma-
tion [24], subcellular localization [25-30] and
phosphorylation [12,30,31]. Based on the results of our
present and previous studies [10], we believe that a rela-
tively large number of nutritional and chemopreventive
anti-cancer agents up-regulate the expression of p27pri-
marily by activating the rate of translation.
4-Hydroxytamoxifen (but not tamoxifen) up-regulates p27
expression by down-regulating eukaryotic translation
initiation repressor protein 4E-BP1 phosphorylated at
Ser65 and this down-regulation is likely to be mediated
by upstream receptor tyrosine kinases/phosphoinositide-
3-kinase/Akt/tuberous sclerosis complex/mammalian
target of rapamycin (RTKs/PI3K/Akt/TSC/mTOR) protein
kinase signaling pathway (pathway #1)
4-Hydroxytamoxifen (but not tamoxifen) up-regulated
expression of p27 in estrogen receptor (ER) -positive as
well as negative breast cancer cells in vitro [also see the
reference [10], suggesting that 4-hydroxytamoxifen up-
regulates the expression of p27 regardless of the status
of estrogen receptor in the breast cancer cells.
The results also indicated that 4-hydroxytamoxifen
(but not tamoxifen) down-regulates eukaryotic transla-
tion initiation repressor protein 4E-BP1 phosphorylated
at Ser65. It was reported in 2001 that co-expression of
the mutant 4E-BP1, which was altered at five different
amino acid positions that are normally the targets for
phosphorylation, up-regulated the expression of p27
through 5’-untranslated region (5’-UTR) in the proximal
upstream region of p27 gene in D6P2T Schwannoma
cells [35]. Based on this observation and our results
taken as a whole, we conclude that down-regulation of
4E-BP1 phosphorylated at Ser65 constitutes an essential
component of the upstream molecular signaling path-
ways of the up-regulation of p27 expression induced by
4-hydroxytamoxifen.
It is worth noting in this respect that decreased phos-
phorylation of 4E-BP1 normally leads to decreased
translation initiation of mRNAs in general, but for p27
the effect is opposite; it leads, instead, to increased
translation initiation of p27 mRNA. This opposite effect
of phosphorylated 4E-BP1 on p27 translation initiation
is likely to be achieved through its unusually long 5’-
untranslated region (5’-UTR) (-575) in the p27 gene
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Page 12 of 19Figure 8 Diagrams showing the overall primary and secondary structures of the 5’-untranslated region (5’-UTR) (-575) of human p27
mRNA. (a) Overall primary structure of human 5’-UTR of p27 gene showing the location of upstream open reading frame (uORF) (-521 to -425)
and the polypyrimidine tract (-66 to -41) in the internal ribosome entry site (IRES) (i.e., IRES region of Hengst: -417 to -1) [11,34]. (b) The most
stable secondary stem and loop structure of the wild-type IRES region of Hengst (-417 to -1) [11,34-36] at several lowest Gibbs free energy
values. This structure was generated using Zucker’s RNA mfold software version 2.3 [56,57]. (c) Same as in Figure 8b, except that UU at -57 and
-56 in the polypyrimidine tract (-66 to -41) were mutated to GG. This mutation completely destroyed the overall secondary stem and loop
structure of IRES. Various other mutations introduced into the polypyrimidine tract also significantly modified the overall stem and loop structure
of IRES.
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motifs, namely uORF (upstream open reading frame)
and IRES (internal ribosome entry site) (Figure 8a).
Combination of these two elements makes it possible
for p27 mRNA to achieve the reverse, cap-independent
translation initiation mechanisms as opposed to the nor-
mal, cap-dependent translation initiation mechanisms of
mRNAs in general.
The critical nucleotide sequence within the IRES motif
in the 5’-untranslated region (UTR) of the p27 gene
resides in the polypyrimidine tract located between -66
and -41 relative to the translation initiation start site
(Figures 8a and 8b) [11,34-36]. If this polypyrimidine
tract is disrupted by mutations, expression of p27 signif-
icantly decreases due to the failure of 40S ribosomal
subunit to recognize and bind to the IRES motif (see,
for example, Figure 8c). In 2005, an article was pub-
lished in which the authors induced two mutations in
what was called “FOXO response element” located at
around -57 relative to the translation initiation start site
of p27 gene. They observed that these mutations signifi-
cantly reduced the p27 promoter activity and stated that
the disruption of this putative FOXO responsive ele-
ment decreased the “transactivation of the FOXO
response element that was present in the p27 promoter”
[37]. Unfortunately, they did not perform gel shift assay
to investigate if any transcription factor binds to this
element. We believe, along with Koff, Miskimins, Hengst
and other investigators [11,34-36], that the transcription
of human p27 gene starts significantly upstream of -51 -
in fact it is -575 in human p27 gene - rather than some-
where between -51 and -1 from the translation initiation
start site. The so-called FOXO responsive element
located at around -51 seems to represent the polypyri-
midine tract within the IRES motif which is located
between -66 and -41 relative to the translation initiation
site.
As for the issue of the upstream molecular signaling
pathways of how 4-hydroxytamoxifen up-regulates the
expression of p27, 4-hydroxytamoxifen seems to down-
regulate phosphorylated 4E-BP1 using upstream recep-
tor tyrosine kinase/phosphoinositide-3-kinase/Akt/
tuberous sclerosis complex/mammalian target of rapa-
mycin (RTKs/PI3K/Akt/TSC/mTOR) protein kinase
signaling pathway (Pathway #1 in Figure 5a, 5b and 7).
This is based on the observation that 4-hydroxytamox-
ifen down-regulated Akt/PKB phosphorylated at
Thr308 without up-regulating AMPKa phosphorylated
at Thr172. The results of our previous study also indi-
cated that inhibitors of several receptor tyrosine
kinases [see also, for example, reference [38],
LY294,002 (inhibitor of PI3K), triciribine (inhibitor of
Akt/PKB), and rapamycin (inhibitor of mTOR) up-
regulated the p27-luciferase reporter activity in
estrogen receptor (ER) -negative MDA-MB-231 human
breast cancer cells in vitro [ 1 0 ] .W ea l s ob e l i e v e ,b u t
could not conclude, that 4-hydroxytamoxifen up-regu-
lated the expression of p27 via MAP kinase pathways
(Pathway #3 in Figures 5b and 7b).
Dexamethasone up-regulates the expression of p27 by
down-regulating phosphorylated eukaryotic translation
initiation repressor protein 4E-BP1 and this down-
regulation is likely to be mediated - primarily - by
upstream 5’-AMP-activated protein kinase/tuberous
sclerosis complex/mammalian target of rapamycin
(AMPK/TSC/mTOR) protein kinase signaling pathway
(pathway #2)
Similar to 4-hydroxytamoxifen, dexamethasone also up-
regulated the expression of p27 in estrogen receptor
(ER) - positive as well as negative breast cancer cells in
vitro [also see the reference [10]. In addition, dexa-
methasone down-regulated eukaryotic translation initia-
tion repressor protein 4E-BP1 phosphorylated at Ser65
through 5-untranslated region (5’UTR) (-575) in the
proximal upstream region of p27 gene.
The effect of dexamethasone on p27 expression
appears to be somewhat different from the effect of 4-
hydroxytamoxifen in terms of the molecular signaling
pathway upstream of 4E-BP1 (Pathways #1 and #2 in
Figures 5a, 5b and 7). Unlike 4-hydroxytamoxifen, dexa-
methasone up-regulated AMPKa phosphorylated at
Thr172. The results of previous studies published by
other investigators seem to agree with our observation
(for example, [39-44]). Since MDA-MB-231 human
breast cancer cells are negative not only in estrogen
receptor (ER), but also in LKB1 (Drosophila par-4
homologue gene), we believe that dexamethasone up-
regulated AMPKa phosphorylated at Thr172 without
activating LKB1. The up-regulation of AMPKa phos-
phorylated at Thr172 by dexamethasone probably led to
the up-regulation of p27 expression by way of tuberous
sclerosis complex (TSC) proteins, mammalian target of
rapamycin (mTOR) and 4E-BP1.
It should be noted that the up-regulation of AMPKa
phosphyrylated at Thr172 by dexamethasone could
indirectly down-regulate Akt/PKB phosphorylated at
Thr308.
In summary, we believe that dexamethasone up-regu-
lated the expression of p27 by down-regulating phos-
phorylated 4E-BP1 and this down-regulation was
mediated primarily by 5’-AMP-activated protein kinase
a/tuberous sclerosis complex/mammalian target of rapa-
mycin (AMPKa/TSC/mTOR) protein kinase signaling
pathway (Pathway #2 in Figures 5a, 5b and 7). The
results of our previous study [10] also indicated that
AMPK is involved in both up and down-regulation of
p27 expression, namely (a) AICAR (aminoimidazole
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(inhibitor of Complex I in mitochondrial oxidative phos-
phorylation), and (c) rapamycin (inhibitor of mTOR)
up-regulated the expression of p27. In contrast, Com-
p o u n dC( i n h i b i t o ro fA M P K )d o w n - r e g u l a t e dt h e
expression of p27 in estrogen receptor (ER) -negative
MDA-MB-231 human breast cancer cells in vitro [10].
Finally, we do not believe that dexamethasone up-
regulated expression of p27 using upstream MAP kinase
pathways (Pathway #3 in Figures 5b and 7b).
Retinoic acids also up-regulate the expression of p27 but
they do so without using any of the pathways described
above for 4-hydroxytamoxifen and dexamethasone
Retinoic acids up-regulated the expression of p27 in
human breast cancer cells in vitro without down-regu-
lating 4E-BP1 phosphorylated at Ser65. Retinoic acids
also did not use upstream molecular signaling pathway
#1 (RTKs/PI3K/Akt/TSC/mTOR) (Figures 5a, 5b and 7),
#2 (AMPK/TSC/mTOR) (Figures 5a, 5b and 7), or -
probably - #3 (MAP kinases) (Figures 5b and 7).
Of the four upstream molecular signaling pathways of
p27 expression identified previously, we investigated
only three pathways (#1, #2 and #3) in the present
study. The pathway #4 was not investigated. Potential
involvement of the pathway #4 in the expression of p27
by retinoic acids was suggested by the results of our
previous study where NSC 119889, an inhibitor of the
global methylation of 5’-m
7G-cap of mRNAs, up-regu-
lated the p27-luciferase reporter activity of the 5’-
untranslated region (5’UTR) (-575) within the proximal
upstream region of the p27 gene (Figures 5b and 7b)
[10].
It is known that nearly all mRNAs are post-transcrip-
tionally modified at their 5’ and 3’ ends by capping and
polyadenylation, respectively [45-47]. The m
7G-capping
at the 5’ end protects the nascent pre-mRNAs against
degradation. Therefore, failure to cap or loss of cap
leads to rapid breakdown of mRNAs. The enzyme 5’-
mRNA cap (guanine-N
7) methyltransferase catalyzes
transfer of methyl group from S-adenosylmethionine
(AdoMet or SAM) to GpppRNA to form m
7GpppRNA.
We observed in our previous study [10] that NSC
119889, a cell-permeable, competitive inhibitor of Ado-
Met (SAM), inhibited global cap-dependent translation
initiation of 5’-m
7G-capped mRNAs in general, but it
increased cap-independent translation initiation of p27
mRNA through its 5’-UTR in estrogen receptor (ER)
-negative MDA-MB-231 human breast cancer cells in
vitro.
Schalinske and other investigators have been reporting
for almost two decades that retinoic acids decrease the
ratio of S-adenosylmethionine (AdoMet or SAM) to S-
adenosylhomocysteine (AdoHcy or SAH) presumably by
inducing glycine N-methyl transferase [48-53]. This
observation suggests that retinoic acids decrease the
ratio of SAM/SAH thereby inducing global hypomethy-
lation of 5’-m
7G-cap of mRNAs, which in turn up-regu-
lates the expression of p27 by increasing reverse, cap-
independent translation initiation of p27 mRNA through
its 5’-UTR.
Based on these considerations, we propose that reti-
noic acids up-regulate the expression of p27 by reducing
the methylation of the 5’-m
7G- c a po fm R N A si ng e n -
eral, and at the same time, increasing the reverse, cap-
independent translation initiation of p27 mRNA through
its 5’-UTR (pathway #4 in Figures 5b and 7b).
Conclusions
Based on the results presented above, we conclude that:
(a) 4-Hydroxytamoxifen (but not tamoxifen) up-reg-
ulates the expression of p27 in both estrogen receptor-
positive and negative human breast cancer cells in
vitro by down-regulating phosphorylation of 4E-BP1
and this down-regulation is mediated by upstream
receptor tyrosine kinases/phosphoinositide 3-kinase/
Akt/tuberous sclerosis complex proteins/mammalian
target of rapamycin (RTKs/PI3K/Akt/TSC/mTOR)
protein kinase signaling pathway (pathway #1 in Fig-
ures 5a, 5b and 7). We also believe, but could not con-
clude, that 4-hydroxytamoxifen up-regulates the
expression of p27 using MAP kinase pathways (Path-
way #3 in Figures 5b and 7b).
(b) Dexamethasone up-regulates the expression of p27
in both estrogen receptor-positive and negative human
breast cancer cells in vitro by down-regulating phos-
phorylation of 4E-BP1 and this down-regulation is
mediated primarily by upstream 5’-AMP-activated
kinase/tuberous sclerosis complex proteins/mammalian
target of rapamycin (AMPK/TSC/mTOR) protein kinase
signaling pathway (pathway #2 in Figures 5a, 5b and 7).
We do not believe that dexamethasone up-regulated
expression of p27 using MAP kinase pathways (Pathway
#3 in Figures 5b and 7b)
(c) Retinoic acids also up-regulate the expression of
p27 in both estrogen receptor-positive and negative
human breast cancer cells in vitro, but they do so with-
out using any of the pathways described above for 4-
hydroxytamoxifen and dexamethasone. We propose that
retinoic acids up-regulate the expression of p27 by
decreasing the ratio of SAM/SAH thereby inducing
hypomethylation of the 5’-m
7G-cap of p27 mRNA.
Hypomethylation of the 5’-cap of p27 mRNA in turn
activates the reverse, cap-independent translation initia-
tion of p27 mRNA through its 5’-untranslated region
(5’-UTR), which contains upstream open reading frame
(uORF) and internal ribosome entry site (IRES) (path-
way #4 in Figures 5b and 7b).
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Reagents
Tamoxifen, 4-hydroxytamoxifen, dexamethasone, all-
trans-retinoic acid (atRA), 9-cis-retinoic acid (9cRA), 13-
cis-retinoic acid (13cRA), and actinomycin D, were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). The
following retinoic acids were generously provided by Dr.
Muccio [30] at the University of Alabama at Birmingham
(Birmingham, AL, USA.): namely 4-methyl-UAB30
(4meUAB30), RA-IV-68A, UAB30, UAB112, UAB76 and
UAB20. The chemical structure and cancer chemopre-
ventive activity of atRA, 9cRA, 13cRA, and other retinoic
acids in the MNU-induced rat mammary adenocarci-
noma in vivo were described in the reference #33.
The following antibodies were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA): namely
(a) total 4E-BP1 and phospho-4E-BP1 (Ser65); (b) total
AMPKa and phospho-AMPKa (Thr172); (c) total Akt
and phospho-Akt (Thr308); (d) total IRS-1 and phos-
pho-IRS-1 (Ser636/639), (e) phospho-PDGFRb (Tyr751),
(f) total PTEN and phospho-PTEN (Ser380), (g) phos-
pho-p44/42MAPK or ERK1/2 (Thr202/Tyr204), (h) total
eIF4E and phospho-eIF4E (Ser209); (i) total eIF2a and
phospho-eIF2a (Ser51) and (j) S6. Additionally, the fol-
lowing two antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA): namely (a)
p27(F-8) and (b) GAPDH.
Cell Cultures
Human MCF7 (estrogen receptor-positive and LKB1-
positive) and MDA-MB-231 (estrogen receptor-negative
and LKB1-negative) breast cancer cell lines were pur-
chased from the American Type Culture Collection
(Rockville, MD, USA). MCF7 cells were grown in Dul-
becco’s Modified Eagle’s Medium (DMEM) containing
4.5 g/L of D-(+)-glucose, supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 mg/L recombi-
nant human insulin, 2% L-glutamine, and antibiotic/
antimycotic solution. MDA-MB-231 cells were grown in
the same culture medium without insulin. The incuba-
tion was carried out at 37°C in a 5% CO2 humidified
chamber. All cells were subcultured after trypsinization
with 0.05% trypsin-0.02% EDTA solution. The cell cul-
tures were always maintained below confluency. The
cells were checked periodically for mycoplasmal infec-
tion by DNA fluorochrome staining.
Plasmids
Luciferase reporter plasmids containing one of the fol-
lowing proximal 5’-upstream region of the p27 gene
were used to transfect the human breast cancer cells:
-1797 p27 (p27-Kpn I) [32], -774 p27 (p27-Apa I) [32],
-575 p27 (p27-5’-UTR) [11,34], -435 p27 (p27-MB) [32],
and -417 p27 (p27-IRES) [11,34] (see Figures 1b and
3a). The control luciferase reporter plasmids that did
not contain these inserts were also prepared to test if
nutritional and chemopreventive anti-cancer agents
were exerting any spurious effects on the backbone
rather than the insert of the luciferase reporter plasmids.
All of the nutritional and chemopreventive anti-cancer
agents tested did not exert spurious effects on the back-
bone of the luciferase reporter plasmid in the human
breast cancer cells in vitro.
Transfection and Luciferase Assay
Transfections were performed according to the pub-
lished protocol [54] using FuGENE 6 purchased from
Roche Applied Science (Indianapolis, IN, USA). Briefly,
24 hours before the transfection of luciferase-reporter
plasmid, cells were seeded into a 60-mm tissue culture
dish containing 3 mL of Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% heatinacti-
vated fetal bovine serum (FBS), 2% L-glutamine, and
antibiotic/antimycotic solution at a density of 1.5 × 10
5
cells/dish and incubated at 37°C in a 5% CO2 humidified
chamber. Transfection was carried out with 1 μg of luci-
ferase reporter plasmid and 0.2 μgo fp S V - b-galactosi-
dase internal control plasmid (Promega, Madison, WI,
USA) mixed with 3 μLo fF u G E N E6s o l u t i o ni n3m L
of FBS-free DMEM supplemented with only 2% L-gluta-
mine. A minimum of 5-hour incubation at 37°C was
needed for transient transfection, followed by 18-hour
incubation in DMEM with 10% FBS for recovery. The
transfected cells were then partially synchronized in
DMEM with 0.2% FBS for 24 hours. The resulting cells
were then treated with various anti-cancer agents in the
same culture medium as described in the figure legends.
After 24 hours, the treated cells were collected and
lysed using Reporter Lysis Buffer (Promega, Madison,
WI). The resulting cell lysates were assayed for lucifer-
ase activity using Luciferase Assay Kit (Promega, Madi-
son, WI, USA) and TD-20/20 Luminometer (Turner
Designs, Sunnyvale, CA, USA). b-Galactosidase activity
was measured using chlorophenol red-b-D-galactopyra-
noside (CPRG) (Sigma-Aldrich, St. Louis, MO, USA) as
substrate.
Each luciferase activity driven by a specific proximal
5’-upstream region of the p27 gene was normalized to
b-galactosidase activity, a control for transfection effi-
ciency. Since certain nutritional and chemopreventive
anti-cancer agents could sometimes stimulate the nor-
malized luciferase activity of empty luciferase reporter
that do not contain any insert of the proximal 5’-
upstream region of the p27 gene, a special formula
[9,10] was used in these exceptional cases to correct for
this false increase in the relative luciferase activity. With
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have not encountered any such exceptional cases.
Western Immunoblot Analysis
Western immunoblot analysis of the upstream molecu-
lar signaling pathways of p27 expression was performed
using estrogen receptor (ER) -negative MDA-MB-231
human breast cancer cells in vitro. The analysis was per-
formed without either transfecting the cells with proxi-
mal 5’-upstream region of p27 gene-luciferase reporter
plasmid or adding growth factors to stimulate the prolif-
eration of the cells.
The cells were first seeded at a density of 5.5 × 10
6
cells/dish into a 100-mm tissue culture dish containing
10 mL of DMEM supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), 2% L-glutamine, and
antibiotic/antimycotic solution and incubated at 37°C in
a5 %C O 2 humidified chamber for 24 hours. After 24
hours, the cells were partially synchronized for another
24 hours in DMEM containing 0.2% FBS. Then, the
cells in the 0.2% FBS-DMEM culture medium were trea-
ted with vehicle (DMSO), tamoxifen, 4-hydroxytamoxi-
fen, dexamethasone, all-trans-retinoic acid (atRA), or 9-
cis-retinoic acid (9cRA) for another 24 hours. After 24
hours, the cells were washed twice with cold 1× PBS
and scraped in 1× RIPA Lysis Buffer (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) containing phenyl-
methylsulphonyl fluoride (PMSF), protease inhibitor
cocktail and sodium orthovanadate, and supplemented
with 50 mM NaF. The cells were then sonicated and the
supernatant was collected by centrifugation and stored
at -80°C.
The supernatants (50 μg protein/lane) were applied to
the SDS-PAGE and, after fractionation, proteins were
transferred to nitrocellulose membrane, which was then
blocked and incubated in a solution containing first pri-
mary antibody. After shaking overnight at 4°C, the target
proteins bound to the first primary antibody were
further treated with alkaline phosphatase (AP)-conju-
gated secondary anti-immunoglobulin antibody and
detected by chemiluminescence using TROPIX Wes-
tern-Star Kit (Applied Biosystems, Foster City, CA, U.S.
A.). After exposure to X-ray film, the blots were
stripped using Western Re-Probe solution (G-Bios-
ciences, St. Louis, MO, U.S.A.), checked for removal of
the chemiluminescence and then re-probed with second
primary antibody.
Densitometric measurement of the intensity of the
bands on the X-ray film was performed using UN-
SCAN-IT Gel & Graph Digitizing Software Version 6.1
(Silk Scientific Corporation, Orem, UT, U.S.A.). Back-
ground corrections were done by four corner interpola-
tion and optical density calculations were performed
using linear standard reflective scan method.
Statistical Analysis
All of the significant P values were between 0.01 and
0.05. So, the results with P values less than 0.05 are sim-
ply indicated as asterisk on top of the vertical bars. The
statistical significance information for the regression
analysis, however, was provided in more detail in the
panel Figure 2c.
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Nonstandard abbreviations
p27: p27Kip1; p21: p21Cip1/Waf1; AMPK: 5’-AMP-acti-
vated protein kinase; TSC: tuberous sclerosis complex;
mTOR: mammalian target of rapamycin; RTK: receptor
tyrosine kinase; PTEN: phosphatase and tensin homolog;
PI3K: phosphoinositide 3-kinase; PKB: protein kinase B;
MAPK: mitogen-activated protein kinase; MEK: mito-
gen-activated protein (MAP) kinase kinase; ERK: ERK
MAP kinase; MNK: MAP kinase interacting kinase;
m
7G: 7-methylguanosine; CDK: cyclin-dependent kinase;
CDI: cyclin-dependent kinase inhibitor; MNU: N-
methyl-N-nitrosourea; atRA: all-trans-retinoic acid;
9cRA: 9-cis-retinoic acid; 13cRA: 13-cis-retinoic acid;
4meUAB30: 4-methylUAB30; ER: estrogen-receptor; 5’-
UTR: 5’-untranslated region; IRES: internal ribosome
entry site; DMSO: dimethyl sulfoxide; pGL3: pGL3 luci-
ferase reporter vector; SV40: simian virus 40; EGFR: epi-
dermal growth factor receptor; PDGFR: platelet-derived
growth factor receptor; IR: insulin receptor; IGR-1R:
type 1 insulin-like growth factor receptor; AdoMet or
SAM: S-(5’-adenosyl)-L-methionine; AdoHcy or SAH: S-
(5’-adenosyl)-L-homocysteine; eIF2a: eukaryotic transla-
tion initiation factor 2a; 4E-BP1: eukaryotic translation
initiation factor 4E binding protein 1; S6K: p70 S6
kinase; AICAR: 5-amino-4-imidazolecarboxamide ami-
noimidazole carboxamide ribonucleotide; Glc: D-(+)-glu-
cose; Ser: L-serine; Thr: L-threonine; Met: L-methionine;
Cys: L-cysteine; Leu: L-leucine; Tyr: L-tyrosine; eIF4E:
eukaryotic translation initiation factor 4E; uORF: 5’-
upstream open reading frame; FBS: fetal bovine serum;
DMEM: Dulbecco’s modified Eagle’s medium; EDTA:
ethylenediaminetetraacetica c i d ;C P R G :c h l o r o p h e n o l
red-b-D-galactopyranoside; bGal: b-galactosidase; Luc:
firefly luciferase; GAPDH: glyceraldehydes phosphate
dehydrogenase.
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